Author:
Nasif Wesam A.,Mukhtar Mohammed H.,El-Emshaty Hoda M.,Alwazna Ahmed H.
Abstract
Background:
Hemodialysis (HD) patients with secondary Hyperparathyroidism (s-HPT) are exposed to increased inflammation and oxidative stress. In HD patients, oxidized albumin is a reliable marker of oxidative stress and its clinical significance has been rarely studied.
Objective:
The objective of this study was to evaluate Cys34 Human Serum Albumin (HSA) as oxidative stress biomarker in HD patients with s-HPT and its relationship with inflammation on bone turnover markers during oral calcitriol supplementation for vitamin D.
Patients and Methods:
Fifteen stable hemodialysis patients with s-HPT (mean age 48.67±8.15, 11 males and 4 females) were used in the experiment to receive calcitriol treatment for 16 weeks (0.25mcg or 0.5 mcg once a day according to serum level of Ca and P for each). The changes in the serum biochemical parameters (Ca, P, ALP, and iPTH), inflammatory markers (CRP and IL-6 levels) and serum oxidative stress condition (SOD, IS and albumin ratio HNA/HMA) were evaluated before and at 8 and 16 weeks of calcitriol treatment. The correlations between those factors were studied.
Results:
All patients responded to oral calcitriol therapy, with a significant decrease in the serum iPTH. The results showed that calcitriol could effectively suppress iPTH secretion with a significant elevation of serum Ca and P but ALP remained unchanged during the study. It can also effectively reduce the inflammatory markers (CRP and IL-6), while increasing the oxidative markers (SOD and IS). Oxidative albumin ratio HNA/HMA showed a significant (p=0.001) reduction after 16 weeks of calcitriol treatment and the redox state of HSA showed a positive prediction for hyperparathyroidism and for inflammation.
Conclusion:
The redox state of HSA could be used as a predictor for monitoring hyperparathyroidism and inflammation during calcitriol treatment by retarding albumin oxidation in HD patients with secondary hyperparathyroidism.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine
Reference42 articles.
1. Nagane NS, Ganu JV, Jagtap PE.
Study of oxidative stress in pre- and post-hemodialysis in chronic renal failure patients.
Biomed Res
2013;
24
: 498-502.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med
2004;
351
(13)
: 1296-305.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
J Am Soc Nephrol
2004;
15
(8)
: 2208-18.
4. Gupta RK, Patel AK, Shah N, et al.
Oxidative stress and antioxidants in disease and cancer: A review.
Asian Pac J Cancer Prev
2014;
15
(11)
: 4405-9.
5. Himmelfarb J, McMonagle E.
Albumin is the major plasma protein target of oxidant stress in uremia.
Kidney Int
2001;
60
(1)
: 358-63.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献